Kura Oncology stock
KURANASDAQKura Oncology, Inc., HealthcareISIN US50127T1097
28Score 28 out of 100, Weak
Price and trend
41 / 100
Price history
−30% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 24% below it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 33).
The price is 45% below its 52-week high. Largest decline in 11 years: 87% (November 2015 to July 2016).
Chart figures for advanced users
- SMA 50$10.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.78
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)33
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.80
- The lowest closing price of the last twelve months.
- Resistance$13.59
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Kura Oncology, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $660.98M, is number 226 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $67.48M (up 25.2% year on year) and a loss of $278.67M.
- MEQIRI Score 28 out of 100 (Weak): rank 706 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $492.1M, financial debt $24.53M.
Weaknesses
- DilutionShare count up 65% since 2020.Capital allocation 18
- Loss-makingLoss of $292.87M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$89.12M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 27 to 28.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 10.1% on the same quarter a year earlier. Revenue turned from negative at the start of the period to positive ($67.48M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −450%, net −413%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Mar 2027in 112 days
- Last reported
- 10 Nov 2026EPS reported −$0.78 (expected −$0.82)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.24−1.0%
- Revenue
- $93.21M−3.0%
- Earnings per share
- −$2.42−1.0%
- Revenue
- $187.77M−9.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +1.6%Guidance maintained: 2026 collaboration revenue of $45 million to $55 million, 2028 trial readout still on track.
“Expect this to be $45 million to $55 million in 2026. $ 90 million to $110 million in 2027, and $90 million to $110 million in 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $2.35M in total. 6 insiders sold, $2.7M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Ford KathleenSale
29 Sept 2026, Chief Operating Officer
- Shares
- 3,668
- Price
- $10.75
- Value
- $39,437
- Leoni MollieSale
29 Sept 2026, Chief Medical Officer
- Shares
- 28,802
- Price
- $10.75
- Value
- $309,567
- Powl Brian T.Sale
29 Sept 2026, Chief Commercial Officer
- Shares
- 15,430
- Price
- $10.75
- Value
- $165,852
Show 15 more
- Bair Teresa BrophySale
28 Sept 2026, Chief Legal Officer
- Shares
- 8,442
- Price
- $10.50
- Value
- $88,618
- Ford KathleenSale
28 Sept 2026, Chief Operating Officer
- Shares
- 6,906
- Price
- $10.50
- Value
- $72,494
- Leoni MollieSale
28 Sept 2026, Chief Medical Officer
- Shares
- 12,448
- Price
- $10.50
- Value
- $130,670
- Doyle Thomas JamesSale
28 Sept 2026, SVP, Finance & Accounting
- Shares
- 4,607
- Price
- $10.50
- Value
- $48,361
- Powl Brian T.Sale
28 Sept 2026, Chief Commercial Officer
- Shares
- 17,020
- Price
- $10.53
- Value
- $179,183
- Burrows FrancisSale
24 Sept 2026, Chief Scientific Officer
- Shares
- 20,726
- Price
- $10.83
- Value
- $224,514
- Wilson Troy EdwardPurchase
24 Aug 2026, President and CEO
- Shares
- 100,000
- Price
- $12.39
- Value
- $1.24M
- Powl Brian T.Sale
21 Aug 2026, Chief Commercial Officer
- Shares
- 4,345
- Price
- $11.89
- Value
- $51,663
- Bair Teresa BrophySale
19 Aug 2026, Chief Legal Officer
- Shares
- 31,487
- Price
- $12.63
- Value
- $397,681
- Wilson Troy EdwardPurchase
17 Aug 2026, President and CEO
- Shares
- 100,000
- Price
- $11.12
- Value
- $1.11M
- Leoni MollieSale
18 Jun 2026, Chief Medical Officer
- Shares
- 84,929
- Price
- $9.82
- Value
- $834,283
- Powl Brian T.Sale
21 May 2026, Chief Commercial Officer
- Shares
- 10,000
- Price
- $11.00
- Value
- $110,000
- Powl Brian T.Sale
19 May 2026, Chief Commercial Officer
- Shares
- 339
- Price
- $9.21
- Value
- $3,122
- Ford KathleenSale
19 May 2026, Chief Operating Officer
- Shares
- 2,257
- Price
- $9.08
- Value
- $20,483
- Bair Teresa BrophySale
18 May 2026, Chief Legal Officer
- Shares
- 2,256
- Price
- $9.38
- Value
- $21,160
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Kura Oncology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 28
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Cullinan TherapeuticsCGEM $697.55M35
- Ginkgo Bioworks HoldingsDNA $690.24M42
- Design TherapeuticsDSGN $689.67M37
- Aclaris TherapeuticsACRS $688.38M39
- Sana BiotechnologySANA $686.16M30
- Wave Life SciencesWVE $674.52M38
- GeronGERN $657.12M35
- Capricor TherapeuticsCAPR $649.77M32
ETFs that hold Kura Oncology
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.05% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.05% | 0.40% | €807M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.04% | 0.35% | €1.21B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.00% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.00% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2016)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.